Article Details

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial - Benzinga

Retrieved on: 2022-02-18 18:16:46

Tags for this article:

Click the tags to see associated articles and topics

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial - Benzinga. View article details on HISWAI: https://www.benzinga.com/general/biotech/22/02/25710456/sanofi-regenerons-dupixent-falls-short-in-chronic-spontaneous-urticaria-trial

Excerpt

The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab) ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up